secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001404644-25-000103
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Q3 2025: $21M net loss; NGN-401 gene therapy shows 35 skill acquisitions, registrational trial started
--------------------------------------------------------------------------------

- Net loss of $21.0M for Q3 2025 vs $20.2M in Q3 2024; R&D expenses $17.2M, G&A $6.6M.
- Positive interim Phase 1/2 data: 35 developmental milestones/skills acquired across 8 pediatric participants; durable CGI-I gains.
- First participant dosed in Embolden registrational trial for Rett syndrome; enrollment expected in 3-6 months.
- Cash, equivalents, investments of $265.4M as of Sep 30, 2025; runway through Q1 2028.
- Preclinical data showed ICV delivery superior to IT-L for AAV biodistribution in key brain regions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/0001404644-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/ngne-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer